X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs FULFORD INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB FULFORD INDIA DR. REDDYS LAB/
FULFORD INDIA
 
P/E (TTM) x 25.3 398.8 6.3% View Chart
P/BV x 3.5 6.2 56.6% View Chart
Dividend Yield % 0.7 0.1 884.8%  

Financials

 DR. REDDYS LAB   FULFORD INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
FULFORD INDIA
Mar-14
DR. REDDYS LAB/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs2,788942 296.0%   
Low Rs1,902450 422.6%   
Sales per share (Unadj.) Rs860.8691.4 124.5%  
Earnings per share (Unadj.) Rs57.111.5 497.9%  
Cash flow per share (Unadj.) Rs122.015.4 794.3%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.90.3 296.8%  
Book value per share (Unadj.) Rs757.7380.0 199.4%  
Shares outstanding (eoy) m165.913.90 4,254.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.0 270.6%   
Avg P/E ratio x41.160.7 67.7%  
P/CF ratio (eoy) x19.245.3 42.4%  
Price / Book Value ratio x3.11.8 169.0%  
Dividend payout %35.017.4 200.8%   
Avg Mkt Cap Rs m389,0342,714 14,332.2%   
No. of employees `00023.50.4 5,298.2%   
Total wages/salary Rs m32,149505 6,366.1%   
Avg. sales/employee Rs Th6,070.86,073.0 100.0%   
Avg. wages/employee Rs Th1,366.61,137.4 120.2%   
Avg. net profit/employee Rs Th402.5100.7 399.8%   
INCOME DATA
Net Sales Rs m142,8102,696 5,296.3%  
Other income Rs m1,552125 1,237.6%   
Total revenues Rs m144,3622,822 5,116.0%   
Gross profit Rs m23,512-46 -50,672.4%  
Depreciation Rs m10,77215 70,868.4%   
Interest Rs m78810 8,294.7%   
Profit before tax Rs m13,50454 24,869.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,38010 45,625.0%   
Profit after tax Rs m9,46845 21,181.2%  
Gross profit margin %16.5-1.7 -956.7%  
Effective tax rate %32.417.7 183.5%   
Net profit margin %6.61.7 399.9%  
BALANCE SHEET DATA
Current assets Rs m104,9841,738 6,039.5%   
Current liabilities Rs m68,938545 12,656.1%   
Net working cap to sales %25.244.3 57.0%  
Current ratio x1.53.2 47.7%  
Inventory Days Days7448 153.4%  
Debtors Days Days1044 2,406.3%  
Net fixed assets Rs m104,38512 877,184.9%   
Share capital Rs m83039 2,128.2%   
"Free" reserves Rs m124,8861,443 8,654.6%   
Net worth Rs m125,7161,482 8,482.9%   
Long term debt Rs m25,0890-   
Total assets Rs m225,4432,077 10,855.8%  
Interest coverage x18.16.7 270.1%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.61.3 48.8%   
Return on assets %4.52.6 174.3%  
Return on equity %7.53.0 249.7%  
Return on capital %9.74.3 225.4%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m72,62317 422,226.7%   
Fx outflow Rs m18,916673 2,810.0%   
Net fx Rs m53,707-656 -8,187.5%   
CASH FLOW
From Operations Rs m18,03090 20,033.3%  
From Investments Rs m-14,883105 -14,228.5%  
From Financial Activity Rs m-4,440-14 31,489.4%  
Net Cashflow Rs m-1,236181 -684.8%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 3.8 142.1%  
FIIs % 35.3 0.1 35,300.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.2 72.2%  
Shareholders   75,885 4,783 1,586.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 18, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS